Laborerhebung zur Häufigkeit von Pneumocystis jirovecii – Zwar ein besonderer Pilz, aber auch ein seltener Erreger?

Zusammenfassung

Pneumocystis jirovecii ist in vieler Hinsicht ein besonderer Pilz. Dieser opportunistische Erreger vermehrt sich im Menschen nur bei bestimmten Grundvoraussetzungen, wobei ein Defekt der T-Zell- abhängigen Infektabwehr besonders stark prädisponiert. Ganz offensichtlich wird die Häufigkeit dieses Erregers unterschätzt, denn eine Erhebung von Untersuchungsergebnissen (IFT und PCR) allein in wenigen Laboratorien im Jahre 2010 ergab eine Zahl von 412 Personen in Deutschland mit einem positiven Erregernachweis. Selbst wenn man annimmt, dass einige davon nur kolonisiert waren, spricht diese hohe Zahl für eine hohe Inzidenz der Pneumocystosis in abwehrgeschwächten Patienten in Deutschland.

Abstract

Pneumocystsis jirovecii is a peculiar fungus for a variety of reasons. This opportunistic pathogen multiplies in humans only under certain conditions; a defect in the T-cell defense system creates a predisposition to this infection. In 2010 a data survey (IFT as well as PCR) from a few laboratories in Germany revealed 412 positive individuals. Even if only a few patients test positive for the colonization stage of this pathogen, the sheer number of individuals testing positive for other stages of infection indicate that the incidence of pneumocystosis in immunocompromised patients in Germany is underestimated.

Schlüsselwörter

Pneumocystis jirovecii - PCR - IFT - Inzidenz

Keywords

Pneumocystis jirovecii - PCR - IFT - Incidence

• Literatur

• 1 Aliouat-Denis C-M, Martinez A, Aliouat EM et al. The pneumocystis life cycle. Mem Inst Oswaldo Cruz 2009; 104: 419-426
• 2 Balabanova Y, Gilsdorf A, Buda S et al. Communicable diseases prioritized for surveillance and epidemiological research: results of a standardized prioritization procedure in Germany, 2011. PLoS One 2011; 6: e25691
• 3 Blum T, Roth A, Mauch H et al. Pneumocystis jiroveci-Pneumonie bei immunsupprimierten Patienten ohne AIDS-Erkrankung – eine Fallserie. DMW 2006; 131: 1515-1520
• 4 Boer de MG, Bruijnesteijn van Coppenraet LE, Gaasbeek A et al. An outbreak of Pneumocystis jiroveci pneumonia with 1 predominant genotype among renal transplant recipients: interhuman transmission or a common environmental source?. Clin Infect Dis 2007; 44: 1143-1149
• 5 Borde JP, Offensperger WB, de With K. Aktuelle Diagnostik und Therapie der Pneumocystis-jirovecii-Pneumonie. DMW 2011; 136: 1426-1430
• 6 Castro de N, Neuville S, Sarfati C et al. Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation: a 6-year retrospective study. Bone Marrow Transplantation 2005; 36: 879-883
• 7 Frenkel JK. Pneumocystis pneumonia, an immunodeficiency-dependent disease (IDD): a critical historical overview. J Eukaryot Microbiol 1999; 46: 89S-92S
• 8 Goldman AS, Goldman LR, Goldman TA. What caused the epidemic of Pneumocystis pneumonia in European premature infants in the mid-20th century?. Pediatrics 2005; 115: 725-736
• 9 Hardak E, Oren I, Dann EJ et al. The increased risk for pneumocystis pneumonia in patients receiving rituximab-CHOP-14 can be prevented by the administration of trimethoprim/sulfamethoxazole: a single-center experience. Acta Haematol 2011; 127: 110-114
• 10 Harigai M, Tanaka Y, Maisawa S. Safety and efficacy of various dosages of ocrelizumab in Japanese patients with rheumatoid arthritis with an inadequate response to methotrexate therapy: A placebo-controlled double-blind parallel-group study. J Rheumatol 2012; 39: 486-495
• 11 Hof H. Pneumocystis jirovecii – ein besonderer Pilz. Pneumocystose – eine Infektion bei Abwehrschwäche. Der Bayerische Internist 2011; 31 Heft 6: 12-17
• 12 Hof H. Pneumocystis jirovecii: a peculiar fungus posing particular problems for therapy and prophylaxis. Mycoses 2012; 54 (Suppl. 01) 1-7
• 13 Krajicek BJ, Thomas CF, Limper AH. Pneumocystis pneumonia: current concepts in pathogenesis, diagnosis, and treatment. Clin Chest Med 2009; 30: 265-278
• 14 Li F, Jin HZ, Su F et al. Pneumocystis pneumonia in patients with immunobullous dermatoses. Int J Dermatol 2011; 50: 1144-1149
• 15 Linssen CF, Jacobs JA, Beckers P et al. Inter-laboratory comparison of three different real-time PCR assays for the detection of Pneumocystis jiroveci in bronchoalveolar lavage fluid samples. J Med Microbiol 2006; 55: 1229-1235
• 16 Marie I, Guglielmino E. Infections opportunistes non tuberculeuses au cours du traitement par les antiTNFα. Rev Med Intern 2010; 21: 353-360
• 17 Matsumoto Y, Matsuda S, Tegoshi T. Yeast glucan in the cyst wall of Pneumocystis carinii. J Protozool 1989; 36: 21S-22S
• 18 Matsumoto Y, Yamada M, Amagai T. Yeast glucan of Pneumocystis carinii cyst wall: an excellent target for chemotherapy. J Protozool 1991; 38: 6S-7S
• 19 Medrano FJ, Montes-Cano M, Conde M et al. Pneumocystis jirovecii in general population. Emerg Infect Dis 2005; 11: 245-250
• 20 Mekinian A, Queyrel V, Durand-Joly I et al. Positive Pneumocystis jirovecii PCR in immunocompromised patients with a systemic disease: infection or colonisation?. Rev Med Interne 2010; 31: 194-199
• 21 Morris A, Norris KA. Colonization by Pneumocystis jirovecii and its role in disease. Clin Microbiol Rev 2012; 25: 297-317
• 22 Phipps LM, Chen SC, Kable K et al. Nosocomial Pneumocystis jirovecii pneumonia: lessons from a cluster in kidney transplant recipients. Transplantation 2011; 92: 1327-1334
• 23 Redhead SA, Cushion MT, Frenkel JK et al. Pneumocystis and Trypanosoma cruzi: nomenclature and typifications. J Eukaryot Microbiol 2006; 53: 2-11
• 24 Sivam S, Sciurba FC, Lucht LA et al. Distribution of Pneumocystis jirovecii in lungs from colonized COPD patients. Diagn Microbiol Infect Dis 2011; 71: 24-28
• 25 Tapparel L, Petignat PA, Praz G. Diagnostic of Pneumocystis jirovecii pneumonia in a non HIV patient. Rev Med Suisse 2010; 6: 1922-1925
• 26 Thomas CF, Limper AH. Current insights into the biology and pathogenesis of Pneumocystis pneumonia. Nat Rev Microbiol 2007; 5: 298-308